Scandinavian Journal of Rheumatology

Editorial
pp. 1-1(1)
Authors: W Müller; M Späth; T Stratz

Physiology and pathophysiology of the 5-HT₃ receptor
pp. 2-8(7)
Authors: L Färber; U Haus; M Späth; S Drechsler

Expression of 5-HT_3A receptors in cells of the immune system
pp. 9-11(3)
Authors: BL Fiebich; RS Akundi; M Seidel; V Geyer; U Haus; W Müller; T Stratz; E Candelario-Jalil

Spectrum of use and tolerability of 5-HT₃ receptor antagonists
pp. 12-18(7)
Authors: U Haus; M Späth; L Färber

Analgesic effects of 5-HT₃ receptor antagonists
pp. 19-23(5)
Authors: K Riering; C Rewerts; W Zieglgänsberger

The influence of the 5-HT₃ receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study
pp. 24-27(4)
Authors: C Koeppe; C Schneider; K Thieme; S Mense; T Stratz; W Müller; H Flor

Antiinflammatory effects of 5-HT₃ receptor antagonists in lipopolysaccharide-stimulated primary human monocytes
pp. 28-32(5)
Authors: BL Fiebich; RS Akundi; K Lieb; E Candelario-Jalil; D Gmeiner; U Haus; W Müller; T Stratz; E Muñoz

Tropisetron inhibits serotonin-induced PGE₂ release from macrophage-like synovial cells in serum-free tissue culture
pp. 33-33(1)
Authors: MF Seidel; G Ulrich-Merzenich; B Fiebich; E Candelario-Jalil; FW Koch; H Vetter

Immunomodulatory function of the 5-HT₃ receptor antagonist tropisetron
pp. 34-40(7)
Authors: EM Schneider; X Ma; T Stratz; W Müller; I Lorenz; WD Seeling

Influence of tropisetron on the serum substance P levels in fibromyalgia patients
pp. 41-43(3)
Authors: T Stratz; B Fiebich; U Haus; W Müller

Local treatment of tendinopathies and myofascial pain
pp. 44-48(5)
Authors: W Müller; T Stratz

Trigger point injection treatment with the 5-HT₃ receptor antagonist tropisetron in patients with late whiplash-associated disorder
pp. 49-50(2)
Author: Th Ettlin

Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT₃ receptor antagonist tropisetron. A double-blind study compared with methylprednisolone
pp. 51-54(4)
Authors: W Samborski; T Stratz; S Mackiewicz; W Müller

Serotonin type 3 receptor antagonist tropisetron in the treatment of chronic inflammatory rheumatic conditions - preliminary clinical experience
pp. 55-58(4)
Author: P Hrycaj

Treatment of systemic sclerosis with the 5-HT₃ receptor antagonist tropisetron
pp. 59-62(4)
Authors: T Stratz; W Müller

Treatment of fibromyalgia with tropisetron - dose and efficacy correlations
pp. 63-66(4)
Authors: M Späth; T Stratz; L Färber; U Haus; D Pongratz

The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience
pp. 67-71(5)
Authors: R Kohnen; L Färber; M Späth

Intravenous treatment of fibromyalgia with the 5-HT₃ receptor antagonist tropisetron in a rheumatological practice
pp. 72-75(4)
Authors: J Tolk; R Kohnen; W Müller

Treatment of chronic low back pain with tropisetron
pp. 76-78(3)
Authors: T Stratz; W Müller

Concluding remarks and outlook for the use of 5-HT₃ receptor antagonists in rheumatology
pp. 79-80(2)
Authors: D Pongratz; T Stratz; W Müller